Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neurol Sci. 2007 Sep 15;260(1-2):143-6. Epub 2007 May 23.

Treatment of spinocerebellar ataxia with buspirone.

Author information

1
Department of Medicine, Division of Neurology, Cooper University Hospital/Robert Wood Johnson Medical School, Camden, New Jersey, USA. Assadi-Mitra@cooperhealth.edu

Abstract

Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.

PMID:
17512011
DOI:
10.1016/j.jns.2007.04.019
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center